Interview: Matthew Stoll - European Medical Journal

This site is intended for healthcare professionals

Interview: Matthew Stoll

4 Mins
Rheumatology
Interviewee:
Matthew Stoll
Citation:

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

You completed joint MD and PhD training in microbiology and immunology before residency and fellowship. How did your early immersion as a laboratory immunologist shape your clinical diagnostic approach?

My research training taught me to be rigorous about evidence and cautious about assumptions, and I think that carries over into my clinical practice. When a diagnosis is uncertain, I would rather take an additional step to clarify it at the outset before committing to it. That becomes particularly important when a patient does not respond to treatment as expected. At that point, I want to be thinking about why the treatment did not work, not going back to determine whether the original diagnosis was correct.

Spondyloarthritis has historically been treated as adult ankylosing spondylitis transposed onto children. What early clinical observations convinced you that juvenile spondyloarthritis represents an immunologically distinct disease process that needs to be treated distinctively?

I actually approach this somewhat differently. Although there are important differences in how spondyloarthritis presents in children and adults, I do not think we have evidence that axial spondyloarthritis in children is an immunologically distinct disease that should necessarily be treated differently. To the contrary, I believe we can learn from the much larger adult evidence base rather than requiring pediatric-specific evidence for every therapeutic decision. Recently, while I was Chair of the Spondyloarthritis Research and Treatment Network (SPARTAN), the organization lent its name to a publication advocating greater alignment between adult and pediatric axial spondyloarthritis clinical trials.

That philosophy was one reason for developing the recent axial spondyloarthritis treatment guidelines with pediatric and adult experts working together. This allows us to extrapolate evidence from adults to children while still accounting for important pediatric considerations.

In recent co-authored work exploring Mendelian randomization in spondyloarthritis, what have been the key methodological challenges in using human genetic variants to infer causal relationships with the gut microbiome?

There are several challenges. One is the problem of multiple comparisons when combining two complex ‘omics’ datasets. Another is uncertainty surrounding the phenotype itself. With the exception of work based on a well-defined genome-wide association study in ankylosing spondylitis, we have to ask how confident we are in the diagnosis of axial spondyloarthritis in many of these Mendelian randomization studies in which cases were identified through diagnostic codes alone.

The microbiota introduces another source of variability. Although the gut microbiota is relatively stable over time at the population level, an individual patient’s microbiota can be affected by factors such as recent antibiotic exposure or dietary changes. Given these potential sources of variation, I find it encouraging that some findings have been reasonably consistent across the literature and have also been supported by Mendelian randomization studies.

Your Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry analysis revealed that 96% of initial TNF inhibitor (TNFi) treatment failures in juvenile spondyloarthritis were secondary non-responses, with female sex and elevated BMI strongly associated with failure. What immunologic mechanisms explain this secondary failure pattern in young females?

Our registry study was not designed to identify the immunologic mechanisms underlying treatment failure, so I would be cautious about attributing these findings to a specific mechanism. What I find particularly interesting is how closely the observations parallel those in adults. Adult studies have likewise found longer TNFi survival in males than in females, and have identified higher BMI as a risk factor for TNFi non-response.

That consistency suggests that these may not be uniquely pediatric phenomena. Understanding the mechanisms behind those associations is an important next question, but our data themselves cannot answer it.

As pediatric Principal Investigator for the 2026 American College of Rheumatology (ACR)/Spondyloarthritis Association of America (SAA)/SPARTAN Axial Spondyloarthritis Guidelines, you reviewed over 14,000 citations. How did your panel establish evidence-based recommendations for children in clinical scenarios where pediatric RCTs are limited?

This is one of the major advantages of developing pediatric and adult recommendations together. Pediatric randomized trial data are limited for many of the clinical questions we face, whereas the adult axial spondyloarthritis literature is more extensive. When direct pediatric evidence was unavailable, the panel could consider evidence from adults and determine when it was reasonable to extrapolate those findings to children, while also considering pediatric-specific issues.

You have presented your temporomandibular joint (TMJ) research at both the ACR Convergence and the international TMJaw Symposium. What challenges remain in standardizing imaging tools like the Juvenile Arthritis MRI Score (JAMRIS) between rheumatologists and maxillofacial surgeons?

One of the fundamental challenges is determining what constitutes an abnormal MRI of the TMJ in a child. The TMJ is difficult to assess clinically because physical examination has limited sensitivity and specificity, which makes imaging particularly important. However, MRI has its own limitations.

Our group previously studied children without arthritis who were undergoing contrast-enhanced brain MRI and found that nearly all had some degree of TMJ contrast enhancement and synovial fluid. Thus, the presence of enhancement or fluid cannot immediately be interpreted as indicating active arthritis.

An additional challenge arises in children with established chronic TMJ arthritis. In those patients, we need to distinguish enhancement caused by active inflammation, which might warrant a change in treatment, from enhancement related to healing or granulation tissue that can be monitored. Better standardization of imaging interpretation is important, but so is improving our understanding of what the imaging findings actually mean biologically and clinically.

ACR Convergence brings together clinicians, scientists, and trainees from around the world. How can congress leadership better structure interactive sessions to encourage clinicians to pursue translational pediatric research?

I think one of the most valuable things a professional organization can do is create opportunities for mentorship and collaboration. For a junior investigator, having access to someone who has successfully navigated the process of developing a research question, obtaining funding, and bringing a project to completion can make an enormous difference.

Programs such as CARRA’s AMIGO mentorship program and SPARTAN’s nascent STAMP program provide models for connecting junior investigators with more experienced mentors. Meetings such as ACR Convergence are particularly valuable because they bring so many people with different expertise together in one place. Creating opportunities for those relationships to begin, and then supporting them after the meeting, can help turn an interesting scientific discussion into an actual research project.

You have actively mentored students through programs like the University of Alabama at Birmingham (UAB) Center for Community Outreach Development (CORD) Summer Research initiative. Why is introducing high school and undergraduate students to immunology early in their education so important?

Training a new student in a research laboratory requires a substantial investment of time and resources. Particularly at the beginning, it would often be faster for an experienced member of the laboratory simply to do the work rather than teaching a trainee to do it.

However, if students leave the laboratory with scientific skills, enthusiasm, and the confidence that they can contribute meaningfully to research, they are much better positioned for their next opportunity, all the more so if they are able to publish their work. The next mentor is then working with someone who already has a foundation on which to build, and this experience gives the trainee an opportunity to determine if this is the path they wish to pursue.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.